Outcomes of Anti-PD1 Treatment for Relapsed/Refractory Hodgkin Lymphoma: A German Hodgkin Study Group (GHSG) Multi-Center Real-World Analysis

Jesko Momotow,Ina Bühnen,Karolin Trautmann-Grill,Guido Kobbe,Martin Wilhelm, Bernhard Heinrich,Tobias Gaska,Helmut Forstbauer,Burkhard Schmidt,Andreas Hüttmann,Gerhard Heil, Doris M. Kraemer,William Hermann Krüger,Vanja Zeremski,Norbert Grobe, Kathleen Jentsch-Ulrich,Michael Fuchs,Bastian von Tresckow,Peter Borchmann,Andreas Engert

Blood（2021）

引用 0|浏览6

暂无评分

摘要

Background: Immune-checkpoint inhibition with antibodies targeting programmed death protein 1 (PD1) was well tolerable and highly effective in pivotal phase II and III trials in relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). We aimed to evaluate emerging therapeutic sequences and the safety and efficacy of anti-PD1 antibodies in the rapidly changing routine care of r/r cHL.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要